Due to spontaneous hydrolysis, active enzyme cholinesterase
is released and this is called reactivation.
The test for the cholinesterase
level is based on the ability of the enzyme to hydrolyze the substrate acetylthiocholine into thiocholine which is then measured utilizing colorimetric analysis.
The search for new cholinesterase
inhibitors is considered an important and ongoing strategy to introduce new drug candidates for the treatment of Alzheimer's disease and other related diseases .
Given the expected worsening of agitation and aggression as AD progresses, the results suggest a clinical benefit of memantine when added to existing cholinesterase
Our search for cholinesterase
inhibitors from Malaysian medicinal plants indicated that the methanol extract of G.
Inhibition of cholinesterase
has been studied in several systems and organs with a focus on brain tissues (Fernandez-Vega et al.
Clinical evidence from nearly 20 years of cholinesterase
inhibitor use suggests that 25% of patients who take them will experience modest cognitive improvements, defined as a 2-to 4-point increase on the Alzheimer's Disease Assessment Scale-cognitive subscale or a 1-to 2-point increase on the Mini-Mental State Exam.
Toxicological screening and cholinesterase
levels help in establishing correct diagnosis.
If employees' red blood cell or serum cholinesterase
levels drop more than 20 percent below their original baseline during a blood test, their employer must investigate and modify pesticide-handling practices.
inhibitors act by blocking an enzyme that breaks down acetylcholine.
In this article, the two classes of drugs currently approved by the Food and Drug Administration for treatment of Alzheimer's disease will be reviewed: the cholinesterase
inhibitors (ChEls) and the single N-methyl-D-aspatate (NMDA) receptor antagonist, the drug memantine (Clip and Save Drug Chart, 2009).
The drugs, cholinesterase
inhibitors such as Reminyl, Exelon and Aricept, can cause serious side effects, according to a study in the May 11 issue of the Archives of Internal Medicine.
Treating patients with mild cognitive impairment (MCI)--the most likely precursor to Alzheimer's disease--with cholinesterase
inhibitors seems to have an initial, but perhaps unsustained, benefit over no treatment (SOR: B, inconsistent results from few trials).
About two-thirds of the participants consumed 1,000 IU vitamin E twice a day along with a cholinesterase
inhibitor drug commonly used to treat their disease.
Four of these medications are called cholinesterase
inhibitors, and are prescribed for mild to moderate AD.